CompletedNot Applicable

PET-FDG in Myocarditis

Canada25 participantsStarted 2018-11-20

Plain-language summary

This study evaluates the diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) with rest perfusion imaging for the diagnosis of myocarditis. Patients with clinical suspicion of myocarditis will be recruited and undergo a rest myocardial perfusion scan and a FDG PET/CT scan following a myocardial suppression protocol.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years of age or older
✓. Clinical suspicion of myocarditis due to findings such as:
✓. Symptoms and signs of myocarditis such as dyspnea, orthopnea, palpitation, and chest pain, without other identifiable cause
✓. New onset of cardiovascular symptoms with recent history of viral disease or previous myocarditis
✓. Unexplained new onset of left ventricular dysfunction
✓. Unexplained elevated troponin
✓. Magnetic resonance imaging findings suggestive of myocarditis, such as late gadolinium enhancement and edema
✓. Biopsy findings compatible with myocarditis

Exclusion criteria

✕. Female subject who is pregnant or breastfeeding and unwilling to stop for 24h
✕. Claustrophobia or inability to lie still in a supine position for imaging purposes
✕. Unwillingness or inability to provide informed consent

What they're measuring

Sensitivity of FDG PET/CT imaging with rest perfusion imaging to detect myocarditis

Timeframe: 1 year

Trial details

NCT IDNCT03777839

SponsorMontreal Heart Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-31

View on ClinicalTrials.gov More Myocarditis trials